FDA Sets PDUFA Date on Aducanumab for Alzheimer Disease
August 07, 2020
Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.